Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.45 |
| ▸ | ARG2 | P78540 | 1/20 | 0.45 |
| ▸ | GGT1 | P19440 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8178078 | 0.98 | ARG1 (0.44) | ARG1ARG2GGT1BLMKDM4E | |
| SCHEMBL8192140 | 0.95 | ARG1 (0.47) | ARG1ARG2GGT1BLMKDM4E | |
| SCHEMBL8821854 | 0.81 | ARG1 (0.42) | ARG1ARG2GGT1 | |
| SCHEMBL537593 | 0.78 | GGT1 (0.39) | ARG1ARG2GGT1BLMKDM4E | |
| SCHEMBL6992677 | 0.78 | GGT1 (0.39) | ARG1ARG2GGT1 | |
| SCHEMBL2638240 | 0.78 | GGT1 (0.39) | ARG1ARG2GGT1BLMKDM4E | |
| SCHEMBL6475315 | 0.78 | GGT1 (0.39) | ARG1ARG2GGT1BLMKDM4E | |
| SCHEMBL7067866 | 0.76 | GGT1 (0.31) | GGT1 | |
| SCHEMBL7617170 | 0.76 | NOS1 (0.47) | GGT1 | |
| SCHEMBL6472209 | 0.76 | GGT1 (0.31) | GGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751930-B1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2000-01-05 | — | — | EP | claimed |
| EP-0751930-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-01-08 | — | — | EP | claimed |
| WO-1995025717-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-09-28 | — | — | WO | claimed |
| US-7862807-B2 | Dendrimers as molecular translocators | UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090311249-A1 | Capecitabine Combination Therapy | ARIAD PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| EP-2032168-A1 | CAPECITABINE COMBINATION THERAPY | ARIAD GENE THERAPEUTICS, INC. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007143212-A1 | CAPECITABINE COMBINATION THERAPY | ARIAD GENE THERAPEUTICS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1545462-A4 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | UNIV CALIFORNIA (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060216265-A1 | Dendrimers as molecular translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-09-28 | — | — | US | disclosed |
| EP-1545462-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | The Regents of the University of California (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6710086-B1 | CHEMICALLY MODIFIED PHARMACOLOGICALLY ACTIVE AGENT IN CARRIER; REDUCE THE DAMAGE TO THE GASTROINTESTINAL TRACT | MEDINOX, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-0751930-B1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999040907-A1 | METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040787-A1 | MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5916910-A | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore | MEDINOX, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1998055453-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0866695-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | Medinox, Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997018805-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | MEDINOX, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0751930-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995025717-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311249-A1 | Capecitabine Combination Therapy | RICTOR, MTOR, EIF4E | ARG1 3126/4885ARG2 2940/4885GGT1 2444/4885 |
| US-20060216265-A1 | Dendrimers as molecular translocators | SLC29A1, SLC29A2, TSPO | ARG1 696/4885ARG2 237/4885GGT1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.